Overview

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Status:
Unknown status

Trial end date:
2019-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on dasatinib.

Phase:

Phase 2

Details

Lead Sponsor:

Shimousa Hematology Study Group

Collaborator:

Epidemiological and Clinical Research Information Network

Treatments:

Dasatinib